Back to top
more

Molina Healthcare (MOH)

(Real Time Quote from BATS)

$156.85 USD

156.85
932,547

+4.54 (2.98%)

Updated Aug 7, 2025 03:39 PM ET

After-Market: $154.88 -1.97 (-1.26%) 4:06 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 1% (243 out of 246)

Industry: Medical - HMOs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Cigna (CI) to Widen Access to Individual Health Plans in 2023

by Zacks Equity Research

Cigna (CI) unveils enhanced individual and family health plans for its customers to opt for in the 2023 Open Enrollment Period. CI will enter newer counties and states to offer better health outcomes.

Zacks Equity Research

Is Molina Healthcare (MOH) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Centene (CNC) Wins Medi-Cal Contracts but Loses 3 Counties

by Zacks Equity Research

Centene (CNC) is likely to appeal the decision to avoid disruption in services and it has time until Sep 1, 2022, to do so.

Zacks Equity Research

QIAGEN's (QGEN) New Syndromic Test to Combat Monkeypox Spread

by Zacks Equity Research

QIAGEN (QGEN) joins the global fight against monkeypox with the launch of its novel QIAstat-Dx Viral Vesicular Panel RUO.

Zacks Equity Research

Teleflex (TFX) Hit by Urolift Volume Decline, Cost Pressure

by Zacks Equity Research

In the Americas, growth within the Surgical business of Teleflex (TFX) is offset by a decline in Interventional Urology.

Zacks Equity Research

Here's How Much You'd Have If You Invested $1000 in Molina a Decade Ago

by Zacks Equity Research

Holding on to popular or trending stocks for the long-term can make your portfolio a winner.

Zacks Equity Research

Edwards Lifesciences (EW) Gets CE Mark for PASCAL Precision

by Zacks Equity Research

Edwards Lifesciences' (EW) PASCAL Precision system enables precise navigation and implant delivery during mitral and tricuspid regurgitation treatment.

Zacks Equity Research

Here's Why Investors Should Retain Hologic (HOLX) Stock for Now

by Zacks Equity Research

Investors are optimistic about Hologic's (HOLX) better-than-expected results and expanded Panther installed base.

Zacks Equity Research

IDEXX (IDXX) Suffers From Macro Headwinds, Cost Constraints

by Zacks Equity Research

The strengthening of the rate of exchange for the U.S. dollar relative to other currencies has a negative impact on IDEXX's (IDXX) revenues.

Zacks Equity Research

What's in the Cards for Medtronic (MDT) in Q1 Earnings?

by Zacks Equity Research

Going by the industry-wide macro trend, we expect Medtronic (MDT) to once again report an adverse effect related to the global supply chain issues in fiscal Q1.

Zacks Equity Research

Boston Scientific (BSX) Signs Obsidio-Acquisition Agreement

by Zacks Equity Research

Boston Scientific's (BSX) latest acquisition will add the FDA-approved GEM technology to its interventional oncology and embolization portfolio.

Zacks Equity Research

Here's Why Investors Should Retain STERIS (STE) Stock for Now

by Zacks Equity Research

Investors are optimistic about STERIS' (STE) robust segmental performance and Cantel Medical buyout.

Zacks Equity Research

Humana (HUM) to Acquire Inclusa to Aid Medicaid Customer Base

by Zacks Equity Research

Humana (HUM) inks a deal to purchase Wisconsin-based Inclusa to grow its Medicaid membership and fortify its footprint in the state.

Zacks Equity Research

Cigna (CI) & Oscar Health Boost Presence in Philadelphia

by Zacks Equity Research

Cigna (CI) & Oscar Health's plans are likely to target businesses with 1-50 employees.

Zacks Equity Research

Humana (HUM) Closes $2.8B Kindred Hospice Divestment to CD&R

by Zacks Equity Research

Humana (HUM) retaining the remaining 40% stake will likely enable it to gain from the standalone company's long-term success.

Zacks Equity Research

Should Value Investors Buy Humana (HUM) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Illumina (ILMN) Q2 Earnings Miss Estimates, Slashes '22 View

by Zacks Equity Research

Robust sales contribution across operating segments drove Illumina's (ILMN) Q2 top line.

Zacks Equity Research

National Vision (EYE) Q2 Earnings Top Mark, Revenue View Cut

by Zacks Equity Research

National Vision (EYE) is simultaneously facing demand headwinds across its network of stores, given the current macro environment, as well as supply challenges.

Zacks Equity Research

ResMed (RMD) Q4 Earnings Beat Estimates, Gross Margin Up

by Zacks Equity Research

ResMed (RMD) posts better-than-expected Q4 results with continued strength in sleep and respiratory care devices sales performance.

Zacks Equity Research

STERIS (STE) Gains From Cantel Buyout, Supply Chain Issue Stays

by Zacks Equity Research

Revenue growth at STERIS' (STE) Applied Sterilization Technologies is driven by increased demand from medical device and biopharma customers.

Zacks Equity Research

Haemonetics (HAE) Q1 Earnings Beat Estimates, Margins Up

by Zacks Equity Research

Haemonetics (HAE) posts better-than-expected results in Q1 with robust contributions from the Hospital business.

Zacks Equity Research

Encompass Health (EHC) Up 4.7% Despite Q2 Earnings Miss

by Zacks Equity Research

Encompass Health (EHC) intends to open three additional de novo locations and increase the bed count by 20 in existing facilities this year.

Zacks Equity Research

Omnicell (OMCL) Q2 Earnings Miss Estimates, Gross Margin Down

by Zacks Equity Research

Robust sales contribution from product and services segments drove Omnicell's (OMCL) Q2 top line.

Zacks Equity Research

SmileDirectClub (SDC) Q2 Earnings Lag Estimates, Guidance Cut

by Zacks Equity Research

SmileDirectClub (SDC) witnesses a drop in both net and financing revenues on a year-over-year basis.

Zacks Equity Research

Insulet (PODD) Q2 Earnings Miss Estimates, '22 Sales View Up

by Zacks Equity Research

Insulet (PODD) posts better-than-expected revenues in Q2 with robust contributions from Total Omnipod.